Effect of passively transferred anti-poliovirus antibodies on seroconversion.
A prospective study enrolling 50 mother-infant pairs was undertaken to determine the effect of maternal antibodies on poliovirus antibody titres and seroconversion rates in infants and to determine the difference in titres and seroconversion rates following three and five doses of oral poliovaccine (OPV). Cord blood samples and samples collected 4 weeks after 3rd and 5th doses of trivalent oral poliovaccine were processed for estimation of anti-poliovirus antibody titres. These were expressed as geometric mean titres (GMT). Significance was analyzed using unpaired 't' test. The relationship between maternal antibody titres and seroconversion was determined by correlation coefficient test. Post OPV5 titres were significantly higher than post OPV3 titres for type 1 and type 2 polioviruses. Seroconversion rates against type 1, 2 and 3 polioviruses were 92.9%, 100.0% and 92.9% following OPV3 and 100.0%, 100.0% and 93.2% following OPV5. The cord blood titres did not have any relation to post-OPV3 or post-OPV5 titres. Although there is significant passive transfer of poliovirus antibodies across the placenta, this does not affect titres achieved after immunization. Post-OPV5 titres against type 1 and type 2 viruses are significantly higher than post-OPV3 titres. The seroconversion rates following OPV5 are higher than those obtained post-OPV3 but this difference is not statistically significant.
Bavdekar
S B
SB
Department of Pediatrics, Seth G.S. Medical College, Parel, Mumbai.
Naik
S
S
Nadkarni
S S
SS
Kamat
J R
JR
Deshpande
J M
JM
Vaswani
L K
LK
D000328:Adult; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007194:India; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D009035:Mothers; D011051:Poliomyelitis / Q000276:immunology* / Q000517:prevention & control; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000276:immunology*; D011247:Pregnancy; D011446:Prospective Studies
D000906:Antibodies; D011055:Poliovirus Vaccine, Oral